Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Background Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized …
C Paul, J Cather, M Gooderham… - British Journal of …, 2015 - academic.oup.com
Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo …
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
AB Gottlieb, RT Matheson, A Menter… - Journal of drugs in …, 2013 - europepmc.org
Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …
Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability …
M Ohtsuki, Y Okubo, M Komine… - The Journal of …, 2017 - Wiley Online Library
Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, works intracellularly
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …
within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo …
[HTML][HTML] Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled …
K Papp, K Reich, CL Leonardi, L Kircik… - Journal of the American …, 2015 - Elsevier
Background Apremilast works intracellularly to regulate inflammatory mediators. Objective
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
ESTEEM 1 evaluated efficacy/safety of apremilast at 30 mg twice a day for moderate to …
Apremilast: a review in psoriasis and psoriatic arthritis
ED Deeks - Drugs, 2015 - Springer
Apremilast (Otezla®) is an oral phosphodiesterase 4 inhibitor indicated for the twice-daily
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …
treatment of adults with psoriasis and psoriatic arthritis (PsA). Its use in these patient …
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
CJ Edwards, FJ Blanco, J Crowley… - Annals of the …, 2016 - ard.bmj.com
Objective To evaluate apremilast treatment in patients with active psoriatic arthritis, including
current skin involvement, despite prior therapy with conventional disease-modifying …
current skin involvement, despite prior therapy with conventional disease-modifying …
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled …
Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized …
K Reich, M Gooderham, L Green… - Journal of the …, 2017 - Wiley Online Library
Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has
demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate …
demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate …